ClinicalTrials.gg
RecruitingNCT06277635Updated Feb 26, 2024

Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases

An interventional study of Silymarin and Placebo in Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis, sponsored by Phramongkutklao College of Medicine and Hospital. Recruiting at 1 site in Thailand. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by Phramongkutklao College of Medicine and Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Arthritis, Rheumatoid with a site in Thailand — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Thailand.

Planned enrollment
33rd of 36
72 · median 651
Started
2024
the only one that year
No phase
2 of 37
1 open now
Registered
36th of 37
by date

Among the 37 studies in Arthritis, Rheumatoid with a site in Thailand, this one is the 33rd largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2024, is one of 2 with no phase, and was the 36th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 37 studies in Arthritis, Rheumatoid with a site in Thailand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Arthritis, Rheumatoid with a site in Thailand, or all of them as a file.
02

Study summary

To study the effect of silymarin against methotrexate-induced liver injury in rheumatic diseases including rheumatoid arthritis, psoriatric arthritis and psoriasis

Read the detailed description
  • Methotrexate was indeed a common and effective treatment for rheumatoid arthritis, psoriatic arthritis and psoriasis. Methotrexate-related hepatotoxicity are common occur 1:1,100 persons. Liver abnormalities varies from asymptomatic liver enzyme elevation to fatal hepatic necrosis and liver fibrosis. Methotrexate was discontinued owing to liver dysfunction in 7.4%
03

Conditions studied

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Psoriasis

Keywords

  • Rheumatoid arthritis
  • Psoriatric arthritis
  • Psoriasis
  • Methotrexate
  • Silymarin
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged > 20 years
  • Diagnosis at least one of the following

    1. Rheumatoid arthritis according to American College of Rheumatology/ The European Alliance of Associations for Rheumatology 2010(ACR/EULAR2010) with at least one joint swelling or tenderness or
    2. Psoriatric arthritis according to CASPAR classification criteria with at least one joint swelling or tenderness, or at least one site dactylitis or enthesitis or Psoriasis by dermatologist with active skin lesion
    3. No previous treatment with methotrexate or treatment with methotrexate within 30 day before randomization
    4. No previous treatment with other conventional synthetic DMARDs other than methotrexate such as sulfasalazine, hydroxycholoquine, leflunomide
    5. No previous treatment with biologic DMARDs such as anti-TNF
    6. Can follow the treatment protocal

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or planning for pregnancy
  • Breastfeeding women
  • Ongoing treatment with active
  • \< 30 ml/min/1.73m2
  • Previous documented of infection
  • Chronic alcohol drinking ≥ 3 times/wk or drug abuse within 6 months prior to randomization
  • Positive of HbsAg, anti
  • Previous documented of preexisting liver disease such as alcoholic liver disease, liver cirrhosis, hepatitis
  • or ALT > ( 0-50 U/L )
  • WBC \< 3,000/ul or \< 100,000 /ul, ANC \< 1,500/ul
  • ILD diagnosed by rheumatologist and pulmonologist from chest X ray and HRCT
  • History documented silymarin or severe adverse effects diagnosed by physician or pharmacist from PMK hospital or from history drug allergy or symptoms such as rash, chest tightness, dyspnea, diarrhea and hypotension
  • Cannot follow up on treatment protocal
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    Silymarin group

    Silymarin 140 mg oral tid pc + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks

    Drug: Silymarin

  • Placebo comparator
    Placebo group

    Placebo + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks

    Drug: Placebo

Interventions

  • Silymarin is randomly assigned to the participants for 12 weeks during study.

    Also known as: Milk Thistle

  • DrugPlacebo

    Placebo is randomly assigned to the participants for 12 weeks during study.

06

What researchers measure

Primary outcomes

  1. AST or ALT > 1X ULN ( normal AST and ALT 0-50 U/L)

    elevation of AST or ALT more than 1X ULN (% participant)

    Time frame: 12 weeks

Secondary outcomes

  1. AST or ALT > 2X ULN ( normal AST and ALT 0-50 U/L) AST or ALT > 2X ULN AST or ALT > 2X ULN

    elevation of AST or ALT more than 2X ULN (% participant)

    Time frame: 12 weeks

  2. AST or ALT > 3X ULN ( normal AST and ALT 0-50 U/L)

    elevation of AST or ALT more than 3X ULN (% participant)

    Time frame: 12 weeks

  3. AST or ALT > 5X ULN or >3X ULN ( normal AST and ALT 0-50 U/L) with symptom of hepatitis such as Fatique, abdominal pain, nausea, vomiting or total bilirubin > 2X with jaundice

    elevation of AST or ALT \> 5X ULN or \>3X ULN with symptom of hepatitis such as Fatique, abdominal pain, nausea, vomiting or total bilirubin \> 2X with jaundice (% participant)

    Time frame: 12 weeks

  4. Discontinuation rate of methotrexate

    Rate of methotrexate discontinuation (%)

    Time frame: 12 weeks

  5. Adverse events

    Rate of any adverse events (%)

    Time frame: 12 weeks

  6. Change of DAS-28 ESR or CRP Score

    Change of DAS-28 ESR or CRP Score for patients with Rheumatoid arthritis and psoriatric arthritis (unit)

    Time frame: 12 weeks

  7. Change of BASDAI Score

    Change of BASDAI Score for AS (unit)

    Time frame: 12 weeks

  8. Change of ASDAS ESR or CRP Score

    Change of ASDAS ESR or CRP Score for AS (unit)

    Time frame: 12 weeks

  9. Change of BSA for psoriasis

    Change of BSA for psoriasis (unit)

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine
    Bangkok, Thailand, 10400, Bangkok 10400, Thailand
    Recruiting
    • Rattapol Pakchotanon, M.D. · Contactrattapolpmk@gmail.com · 66+23547980
    • Rattapol Pakchotanon, M.D. · Sub investigator
    • Supasa Niyompanichakarn, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Study Protocol is to be shared with others. Full data would become available by mid 2026.

Supporting information: Study protocol

Time frame: mid 2026

Access criteria: IPD Sharing Access Criteria has not been decided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Apr 2025, 14 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 14 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Feb 26, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Feb 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06277635
Lead sponsor
Phramongkutklao College of Medicine and Hospital
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Feb 1, 2024
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Feb 26, 2024

Study contacts

Rattapol Pakchotanon, M.D.
Contact
rattapolpmk@gmail.com
66+2 354 7980
Chatpong Makmee, M.D.
Contact
chatpongmakmee17@gmail.com
0862204693
Rattapol Pakchotanon, M.D.
study director · Phramongkutklao College of Medicine and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silymarin

Start the discussion